Photocure Boosts U.S. Footprint with Equipment Expansions Amid Regulatory Shifts
Event summary
- Photocure reported Q2 2026 revenues of NOK 142.5 million, up from NOK 135.6 million in Q2 2025.
- Installed 6 new Saphira towers in the U.S., bringing total active accounts to 436 (up 20% YoY).
- Acquired Vesica Health, developer of AssureMDx, a multi-omic urine-based biomarker test for bladder cancer.
- FDA confirmed plans to reclassify BLC equipment in H2 2026, potentially expanding Photocure's addressable market.
The big picture
Photocure's strategic moves align with broader trends in precision diagnostics, where non-invasive biomarker testing and advanced imaging technologies are converging to improve bladder cancer detection and management. The FDA's regulatory evolution could unlock significant market expansion, while the acquisition of Vesica Health positions Photocure as a leader in building an integrated diagnostic platform.
What we're watching
- Regulatory Tailwinds
- How FDA's BLC reclassification will affect equipment manufacturer participation and adoption rates.
- Integration Challenges
- The pace at which Vesica Health's AssureMDx can be integrated into Photocure's precision diagnostics platform.
- Revenue Timing
- Whether AssureMDx can achieve earlier-than-expected reimbursement and generate initial revenue in 2027.
Related topics